Join the club for FREE to access the whole archive and other member benefits.

Nature Biotechnology reviews the state of play of senolytics

12-Nov-2020

Key points from article :

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing joint pain and stiffness.

Inhibiting MDM2 risks unleashing indiscriminate cell killing in off-target, non-senescent tissues.

Unity is now focused on the development of its BCL-xL inhibitor UBX1325 for retinal diseases.

More than two dozen other startups continue to pursue approaches to target senescent cells.

University of Florida trying to make BCL-xL blockade safer for systemic administration.

Peter de Keizer described a cell-permeable peptide comprising part of FOXO4 that could disrupt this process.

He started Cleara Biotech to make the drug more stable and targeted by introducing more unusual amino acids.

Uğur Sezerman started a company called Eternans centered around a peptide drug that directly binds to FOXO4.

To identify senescent cells, many researchers rely on imperfect proxies.

Lars Zender has developed a radioactive form of β-galactosidase that can be tracked non-invasively in the body.

Mentioned in this article:

Click on resource name for more details.

Amit Sharma

Group Lead at SENS Research Foundation.

Andrew Koff

Professor at Memorial Sloan-Kettering Cancer Center and founder of Atropos Therapeutics.

Anil Bhushan

Professor at UCSF and co-founder of Deciduous Therapeutics.

Anirvan Ghosh

Chief Executive Officer at UNITY Biotechnology.

Atropos Therapeutics

Biopharmaceutical company focused on discovering and developing drugs against aging disorders and cancer.

Christopher Wiley

Research Assistant Professor at Buck Institute for Research on Aging

Cleara Biotech

Cleara is developing therapeutics to eliminate senescent cells.

Daohong Zhou

Professor of Pharmacodynamics and Radiation Oncology at the University of Florida.

Deciduous Therapeutics

Company developing a novel class of immune-modulatory therapies designed to promote a healthy lifespan.

Dorian Therapeutics

Anti-aging company developing senoblockers.

Eternans

Biotechnology company developing senolytic agents.

Guangrong Zheng

Associate Professor of Medicinal Chemistry at University of Florida.

James Kirkland

Researcher on different aging related diseases.

Jennifer H. Elisseeff

Morton Goldberg Professor, Johns Hopkins University

Lars Zender

Director and Chair in Department of Medicine at the University of Tübingen.

Lewis Gruber

CEO, CSO and Co-Founder of SIWA Therapeutics

Lorna Harries

Professor of Molecular Genetics at the University of Exeter.

Manuel Serrano

Director, Institute for Research in Biomedicine

Marco Demaria

Group Leader and Associate Professor at European Research Institute for the Biology of Ageing (ERIBA).

Matthew Scholz

Founder and Chief Executive Officer at Oisín Biotechnologies

Michel Sadelain

Immunologist and director at Center for Cell Engineering

Nir Barzilai

Founding director of the Institute for Aging Research.

Oisin Biotechnologies

Drug development company focused on the senolytic technology to fight age-related diseases

Oncosence

Company that target cancer by developing senescence inducing and senolytic (senescent cell killing) compounds.

Osman Ugur Sezerman

Associate Professor at Acibadem University.

Paul Robbins

Professor of Biochemistry, Molecular Biology and Biophysics at the University of Minnesota.

Peter de Keizer

Associate Professor at UMC Utrecht, Founder and Managing Director at Cleara Biotech

Rene Bernards

Professor of Molecular Carcinogenesis at the Netherlands Cancer Institute.

Scott Lowe

Cancer biologist and chair of cancer biology & genetics program at Memorial Sloan Kettering Cancer Center in US

SENISCA

University of Exeter spinout aiming to develop senotherapeutic interventions

Senolytic Therapeutics (Senolytx)

Pharmaceutical company that develops a novel class of medicines by targeting damaged cells.

SIWA Therapeutics

Biotechnology company producing therapy that targets and destroys senescent cells.

University of Florida (UF)

Public land grant university in Gainesville, Florida.